Worcester, MA - July 7, 2025 - Mustang Bio, Inc., a clinical-stage biopharmaceutical company, announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its MB-101 (IL13Ra2-targeted CAR T-cells) therapy. This designation is for the treatment of recurrent diffuse and anaplastic astrocytoma and glioblastoma (GBM). Previously, the FDA also granted Orphan Drug Designation for Mustang's MB-108 for the treatment of malignant glioma. This recognition validates Mustang Bio's innovative approach, which combines MB-101 and MB-108 to potentially improve treatment outcomes for patients with challenging cancers. The development of the MB-109 program for recurrent GBM and high-grade astrocytomas will depend on securing additional funding or strategic partnerships.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.